IHH Healthcare, one of Asia’s leading and largest multinational healthcare providers, has continued expanding its footprint across North Asia.
In October, it officiated the opening of its first ambulatory care centre in Hong Kong, Gleneagles MediCentre, which features a new model of care delivered closer to where people live and work.
To bring smarter, more accessible healthcare to the community, the MediCentre – the first private day medical centre in Hong Kong offering a pre-anaesthesia clinic – delivers a range of ambulatory services, including oncology outpatient consultation and chemotherapy, endoscopy, minor surgeries and medical aesthetics.
Its seamless integration of AI and augmented reality (AR) technologies – from digital registration and voice-to-text clinical notetaking to AR navigation that guides patients effortlessly throughout their journey – is what makes the centre unique.
IHH Healthcare Group CEO Dr Prem Kumar Nair said: “The grand opening of our Gleneagles MediCentre in Admiralty is a powerful reflection of several key focus areas in IHH’s ongoing transformation. The Centre marks another milestone in our out-of-hospital new care model, bringing high-quality day treatments and specialist services closer to where people live and work. It also showcases how AI and digital technologies are seamlessly embedded into clinical workflows to drive greater efficiency, improved outcomes and enhanced patient experience.”
Making healthcare smarter
In recent years, the Hong Kong Trade Development Council (HKTDC) has been supporting IHH Healthcare, including facilitating important partnerships, to bring smart, connected and compassionate care to the public.
The HKTDC first introduced Gleneagles Hospital Hong Kong to PanopticAI – a Hong Kong healthtech firm associated with The Hong Kong University of Science and Technology (HKUST) – at the Asia Summit on Global Health (ASGH) in 2022, initiating several rounds of meetings between the two parties.
On HKTDC’s advice, Gleneagles signed a memorandum of understanding (MoU) with the medical-grade health monitoring tech provider to apply its research results in its Hong Kong hospitals and provide next-gen digital healthcare solutions to the public.
The success of the MoU has led to another agreement with PanopticAI in 2025, this time to introduce SmartCare Technology.
A healthtech firm nurtured by HKUST, SmartCare Technology provides advanced multimodal large language models to deliver a seamless consultation experience.
A cooperation agreement, facilitated by the HKTDC, was signed by the three parties at ASGH 2025, which takes place every May to bring together leading voices in healthcare from around the world to engage in dialogue and find partners and investors.
The collaboration involves the integration of AI technologies of PanopticAI and SmartCare to develop Smart Clinic solutions and AI-assisted digitalisation of clinical workflows, to be piloted at the recently opened Gleneagles MediCentre.
At last year’s ASGH, the HKTDC introduced Dr Kenneth Tsang, IHH Healthcare North Asia Regional CEO and Gleneagles Hospital Hong Kong CEO, to Emerging Viral Diagnostics Limited (EVDL)’s Co-Founder and President Prof Terence Lau.
Biotech firm EVDL focuses on the R&D and commercialisation of diagnostics products and services based on genetics and molecular biology.
They started to engage in discussions and agreed to kickstart a 3-month proof of concept program by June 2024. EVDL’s diagnostics machine was installed at Gleneagles Hospital Hong Kong the following month.
The initial partnership proved to be a success, which, upon HKTDC’s advice, led to an agreement being signed by the two entities at ASGH in May this year, to adopt the innovative diagnostics system developed by EVDL for Gleneagles Hospital Hong Kong's laboratory and telemedicine services.
Also at ASGH 2025, Gleneagles and longevity biotech firm GUTolution made initial contact, which led to the signing of an MoU at the Belt and Road Summit in September to incorporate personalised gut health interventions – including GUTolution’s advanced microbiome testing – into the services to be offered by a Gleneagles’ wellness institute.
Gleneagles Hospital Hong Kong has been a supporter of ASGH since the Summit’s inaugural edition in 2021 as Future Private Health Partner. Dr Nair is an Honorary Advisor, while Dr Tsang serves on the ASGH Steering Committee. Both have spoken at the event to share their insights on the latest innovations and trends in healthcare.
Dr. Tsang remarked: “We have found a fantastic partner in the Hong Kong Trade Development Council. We appreciate their steadfast support of Gleneagles’ vision. They have connected us with new partners and projects, enabling us to grow further”.
The next edition of ASGH will take place on 11-12 May.